Furthermore, investigations into PD-L1 mutations, found in up to 20–25% of UTUC tumors and associated with worse survival, have highlighted this as a potential target for immunotherapy [111,112], as well as targeting HER2 with trastuzumab [113]. Here, CD274 is linked to renal pelvis/ureter urothelial carcinoma.